One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Amarin Corporation plc logo
Amarin Corporation plc AMRN
$ 11.55 -0.09%
report update icon

Quarterly report 2026-Q3
added 10-28-2026

Amarin Corporation plc Balance Sheet 2025-2008 | AMRN

Brief overview of Amarin Corporation plc's balance sheet structure

This overview follows the five latest available annual observations between 2021 and 2025.

Assets fell from $1.1 billion to $670.8 million. This may reflect either deliberate optimization or a reduction in business scale.

Liability growth of -47.3% trailed asset growth of -37.2%. The funding structure became more resilient.

Equity accounts for 68.5% of assets. Against the initial 62.5%, the capital position looks resilient.

The cash share moved from 20.5% to 20.1%. A higher figure generally provides more room in an adverse scenario.

Retained earnings remain negative at -$1.7 billion. This may reflect past losses or substantial shareholder distributions, so earnings and buybacks provide important context.

Conclusion

Amarin Corporation plc's financial position is more positive than negative: the funding mix is workable, although the cushion is not unlimited.

Annual Balance Sheet Amarin Corporation plc

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

Net Debt

-126 M -111 M -189 M -206 M -211 M -176 M -594 M -169 M 49 M 18.2 M 144 M 115 M 69.6 M -23.7 M -116 M -31.4 M - -

Long Term Debt

6.08 M 7.72 M 8.74 M 10 M 8.58 M 9.15 M - 46.1 M 99.8 M 85.2 M 236 M 219 M 248 M 234 M 800 K 88 K - -

Long Term Debt Current

2.15 M 1.95 M 1.87 M 1.57 M - 1.48 M 50.1 M 34.2 M 22.3 M 15.9 M 14.7 M 15.4 M - - - - - -

Total Non Current Liabilities

17 M 19.2 M 20.3 M 31.4 M 30.3 M 31.1 M 31.7 M 76.1 M 118 M 99.8 M 250 M 219 M 249 M 290 M 124 M 230 M - -

Total Current Liabilities

194 M 180 M 259 M 259 M 371 M 307 M 242 M 157 M 109 M 76.2 M 50.7 M 40.3 M 37.5 M 25.2 M 8.45 M 7.58 M - -

Total Liabilities

211 M 199 M 280 M 291 M 401 M 339 M 274 M 233 M 227 M 176 M 301 M 260 M 286 M 315 M 132 M 238 M - -

Deferred Revenue

- - 2.34 M 2.2 M 2.65 M 2.93 M 2.34 M 1.22 M 1.64 M 1.17 M 923 K - 1.7 M - - - - -

Retained Earnings

-1.71 B -1.67 B -1.59 B -1.53 B -1.42 B -1.43 B -1.41 B -1.39 B -1.27 B -1.2 B -1.12 B -970 M -914 M -748 M -568 M -499 M - -

Total Assets

671 M 685 M 832 M 886 M 1.07 B 966 M 882 M 386 M 162 M 167 M 173 M 171 M 252 M 311 M 126 M 35.4 M - -

Cash and Cash Equivalents

135 M 121 M 199 M 218 M 219 M 187 M 645 M 249 M 73.6 M 98.3 M 107 M 120 M 192 M 260 M 117 M 31.4 M 52.3 M 14.2 M

Book Value

459 M 486 M 552 M 595 M 667 M 628 M 608 M 152 M -65.1 M -9.06 M -128 M -88.4 M -33.8 M -4 M -5.9 M -202 M - -

Total Shareholders Equity

459 M 486 M 552 M 595 M 667 M 628 M 608 M 152 M -65.1 M -9.06 M -128 M -88.4 M -33.9 M -4 M -5.96 M -202 M 6.6 M 8.42 M

All numbers in USD currency

Quarterly Balance Sheet Amarin Corporation plc

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

5.35 M 5.26 M 5.58 M 6.08 M 6.73 M 7.34 M 7.94 M 7.72 M 8.22 M 8.1 M 8.39 M 8.74 M 8.97 M 9.47 M 9.84 M 10 M 9.92 M 10.2 M 10.4 M 8.58 M 8.73 M 8.88 M 9.02 M 9.15 M 9.26 M 9.31 M 9.38 M 9.44 M 9.43 M 8.16 M 7.93 M 79.7 M 83.4 M 86.7 M 89.1 M 92.4 M 95.2 M 94.6 M 94.1 M 93.6 M 93.1 M 92.5 M 92 M 91.5 M 91 M 90.5 M 90.1 M 89.6 M 89.2 M 88.7 M 88.2 M 87.7 M 87.3 M 86.7 M 85.9 M 85.2 M 131 M 127 M 124 M 764 K 559 K 478 K -

Total Non Current Liabilities

14.5 M 16.6 M 16.7 M 17 M 18.7 M 19.3 M 19.6 M 19.2 M 17.7 M 17.4 M 19.7 M 20.3 M 19.2 M 20 M 31.2 M 31.4 M 33.1 M 31.6 M 32 M 30.3 M 28.6 M 29.2 M 29.9 M 31.1 M 26.8 M 28.6 M 29.6 M 31.7 M 41.3 M 56 M 69.6 M 76.1 M 111 M 113 M 113 M 118 M 123 M 123 M 126 M 99.8 M 104 M 234 M 255 M 250 M 238 M 236 M 235 M 219 M 219 M 218 M 246 M 249 M 280 M 274 M 289 M 290 M 222 M 248 M 316 M 124 M 156 M 286 M -

Total Liabilities

190 M 181 M 196 M 211 M 201 M 205 M 182 M 199 M 219 M 248 M 244 M 280 M 286 M 291 M 275 M 291 M 320 M 393 M 333 M 401 M 393 M 400 M 356 M 339 M 353 M 312 M 340 M 274 M 271 M 241 M 231 M 233 M 263 M 251 M 232 M 227 M 213 M 209 M 204 M 176 M 179 M 312 M 309 M 301 M 294 M 287 M 277 M 260 M 255 M 256 M 278 M 286 M 312 M 309 M 331 M 315 M 255 M 266 M 325 M 132 M 162 M 290 M 132 M

Deferred Revenue

- - - - - - - - - - 2.34 M 2.34 M 2.02 M 2.02 M 2.2 M 2.2 M 2.2 M 2.2 M 2.2 M 2.65 M 2.65 M 2.64 M 2.77 M 2.93 M 5.71 M 5.71 M 4.29 M 2.34 M 1.96 M 1.96 M 1.9 M 1.22 M 1.22 M 1.06 M 1.45 M 1.64 M 2.22 M 1.45 M 1.2 M 1.17 M 1.17 M 1.17 M 1.17 M 923 K 923 K 856 K 923 K - - - - 1.7 M 1.62 M 1.83 M 2.86 M - - - - - - - -

Retained Earnings

-1.73 B -1.73 B -1.72 B -1.71 B -1.71 B -1.7 B -1.68 B -1.67 B -1.62 B -1.59 B -1.6 B -1.59 B -1.58 B -1.56 B -1.54 B -1.53 B -1.53 B -1.52 B -1.45 B -1.42 B -1.44 B -1.42 B -1.43 B -1.43 B -1.43 B -1.43 B -1.43 B -1.41 B -1.42 B -1.41 B -1.41 B -1.39 B -1.35 B -1.33 B -1.3 B -1.27 B -1.25 B -1.24 B -1.22 B -1.2 B -1.18 B -1.16 B -1.15 B -1.12 B -1.1 B -1.07 B -1 B -970 M -951 M -925 M -940 M -914 M -898 M -850 M -810 M -748 M -737 M -711 M -657 M -568 M -587 M -683 M -568 M

Total Assets

634 M 624 M 646 M 671 M 660 M 670 M 656 M 685 M 751 M 800 M 790 M 832 M 839 M 860 M 860 M 886 M 908 M 973 M 974 M 1.07 B 1.04 B 1.04 B 990 M 966 M 960 M 915 M 926 M 882 M 867 M 390 M 372 M 386 M 210 M 204 M 216 M 162 M 167 M 170 M 175 M 167 M 194 M 148 M 153 M 173 M 182 M 195 M 215 M 171 M 185 M 206 M 220 M 252 M 294 M 215 M 271 M 311 M 255 M 271 M 261 M 126 M 132 M 136 M 126 M

Cash and Cash Equivalents

157 M 144 M 131 M 135 M 123 M 148 M 120 M 121 M 157 M 216 M 214 M 199 M 271 M 233 M 191 M 218 M 240 M 228 M 219 M 219 M 223 M 327 M 291 M 187 M 207 M 214 M 329 M 645 M 673 M 222 M 211 M 249 M 81.9 M 102 M 130 M 74.2 M 79.1 M 85.5 M 96.7 M 98.9 M 118 M 72.5 M 81.4 M 107 M 119 M 136 M 161 M 120 M 135 M 151 M 164 M 192 M 226 M 149 M 202 M 260 M 215 M 250 M 246 M 117 M 126 M 131 M 117 M

Book Value

444 M 444 M 449 M 459 M 459 M 465 M 474 M 486 M 531 M 552 M 546 M 552 M 553 M 569 M 585 M 595 M 588 M 580 M 641 M 667 M 642 M 645 M 635 M 628 M 607 M 603 M 586 M 608 M 596 M 149 M 141 M 152 M -52.8 M -46.7 M -16.7 M -65.1 M -46.1 M -38.8 M -28.8 M -9.06 M 15.2 M -164 M -156 M -128 M -111 M -91.4 M -61.8 M -88.4 M -69.2 M -50 M -57.6 M -33.9 M -17.7 M -94.3 M -60.1 M -4 M 38 K 5.32 M -64.4 M -5.96 M -30.3 M -155 M -5.96 M

Total Shareholders Equity

444 M 444 M 449 M 459 M 459 M 465 M 474 M 486 M 531 M 552 M 546 M 552 M 553 M 569 M 585 M 595 M 588 M 580 M 641 M 667 M 642 M 645 M 635 M 628 M 607 M 603 M 586 M 608 M 596 M 149 M 141 M 152 M -52.8 M -46.7 M -16.7 M -65.1 M -46.1 M -38.8 M -28.8 M -9.06 M 15.2 M -164 M -156 M -129 M -111 M -91.4 M -61.8 M -88.4 M -69.2 M -50 M -57.6 M -33.9 M -17.7 M -94.3 M -60.1 M -4 M 38 K 5.32 M -64.4 M -5.96 M -30.3 M -155 M -5.96 M

All numbers in USD currency

Balance Sheet is a fundamental financial report of Amarin Corporation plc, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
Passage Bio Passage Bio
PASG
$ 3.9 12.72 % $ 12.5 M usaUSA
Vaxcyte Vaxcyte
PCVX
$ 63.86 3.13 % $ 8.69 B usaUSA
Relay Therapeutics Relay Therapeutics
RLAY
$ 18.59 9.32 % $ 3.19 B usaUSA
Precigen Precigen
PGEN
$ 4.47 5.81 % $ 1.4 B usaUSA
Avidity Biosciences Avidity Biosciences
RNA
$ 8.36 0.48 % $ 1.15 B usaUSA
Phio Pharmaceuticals Corp. Phio Pharmaceuticals Corp.
PHIO
$ 0.8 -1.38 % $ 4.79 M usaUSA
Praxis Precision Medicines Praxis Precision Medicines
PRAX
$ 277.94 5.85 % $ 6.25 B usaUSA
Prelude Therapeutics Incorporated Prelude Therapeutics Incorporated
PRLD
$ 3.59 0.98 % $ 276 M usaUSA
ProQR Therapeutics N.V. ProQR Therapeutics N.V.
PRQR
$ 1.36 1.88 % $ 143 M niderlandNiderland
Ocular Therapeutix Ocular Therapeutix
OCUL
$ 6.61 2.8 % $ 1.24 B usaUSA
PolyPid Ltd. PolyPid Ltd.
PYPD
$ 6.08 7.23 % $ 99.4 M israelIsrael
Outlook Therapeutics Outlook Therapeutics
OTLK
$ 0.44 -0.93 % $ 15.3 M usaUSA
uniQure N.V. uniQure N.V.
QURE
$ 21.68 3.19 % $ 1.25 B niderlandNiderland
Ultragenyx Pharmaceutical Ultragenyx Pharmaceutical
RARE
$ 15.48 -0.58 % $ 1.53 B usaUSA
Rafael Holdings Rafael Holdings
RFL
$ 1.02 -4.67 % $ 52.4 M usaUSA
REGENXBIO REGENXBIO
RGNX
$ 7.62 3.25 % $ 393 M usaUSA
Rigel Pharmaceuticals Rigel Pharmaceuticals
RIGL
$ 39.52 -13.54 % $ 711 M usaUSA
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA
Генетико Генетико
GECO
- - - russiaRussia
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Tenax Therapeutics Tenax Therapeutics
TENX
$ 1.68 3.07 % $ 65.9 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Scholar Rock Holding Corporation Scholar Rock Holding Corporation
SRRK
$ 46.77 2.78 % $ 5.36 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Spero Therapeutics Spero Therapeutics
SPRO
$ 1.03 1.47 % $ 57.7 M usaUSA
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
- 0.74 % $ 768 M israelIsrael
Abcam plc Abcam plc
ABCM
- - $ 4.9 B britainBritain
Rezolute Rezolute
RZLT
$ 3.85 5.77 % $ 400 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Tiziana Life Sciences PLC Tiziana Life Sciences PLC
TLSA
$ 0.69 11.43 % $ 73.6 M britainBritain
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Affimed N.V. Affimed N.V.
AFMD
- -34.95 % $ 21.5 M germanyGermany
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
- -1.58 % $ 28.1 M chinaChina
Celyad Oncology SA Celyad Oncology SA
CYAD
- - $ 12.5 M belgiumBelgium
Seer Seer
SEER
$ 1.63 0.18 % $ 90.4 M usaUSA
Gracell Biotechnologies Gracell Biotechnologies
GRCL
- - $ 3.37 B chinaChina
Stoke Therapeutics Stoke Therapeutics
STOK
$ 26.51 1.69 % $ 1.57 B usaUSA
Sutro Biopharma Sutro Biopharma
STRO
$ 9.57 4.08 % $ 81.3 M usaUSA
Silence Therapeutics plc Silence Therapeutics plc
SLN
$ 19.73 0.03 % $ 2.8 B britainBritain
Taysha Gene Therapies Taysha Gene Therapies
TSHA
$ 4.34 6.11 % $ 1.39 B usaUSA
Soligenix Soligenix
SNGX
$ 0.34 0.54 % $ 1.76 M usaUSA
Spruce Biosciences Spruce Biosciences
SPRB
$ 46.46 8.78 % $ 35.6 M usaUSA
Supernus Pharmaceuticals Supernus Pharmaceuticals
SUPN
$ 26.14 -2.24 % $ 1.48 B usaUSA
Galapagos NV Galapagos NV
GLPG
- - $ 1.83 B belgiumBelgium
Savara Savara
SVRA
$ 4.82 9.93 % $ 1.07 B usaUSA
Viking Therapeutics Viking Therapeutics
VKTX
$ 26.86 4.15 % $ 3.03 B usaUSA
Teligent, Inc. Teligent, Inc.
TLGT
- -13.85 % $ 16.1 M usaUSA
Viela Bio, Inc. Viela Bio, Inc.
VIE
- - $ 2.91 B usaUSA